Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Colorectal Cancer Metastatic
Clinical trial register · China

Colorectal Cancer Metastatic Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Guangzhou 6 Beijing 6 Hangzhou 4 Jinhua 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Guangzhou6 Beijing6 Hangzhou4 Jinhua1
All 11 locations
Target enrolment
to

Colorectal Cancer Metastatic trials in China

29 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fujian Medical University Union Hospital
Observational
610
Fuzhou
2027-01-01
Not yet open
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
NCT07729605Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 3
270
Guangzhou
2026-07-30
Not yet open
Peking University Cancer Hospital & Institute
Phase 2
17
Beijing
2026-07-28
Not yet open
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
120
Beijing
2026-07-15
Recruiting
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
NCT06889610Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
Fudan University
Phase 2
95
Shanghai
2026-03-30
Recruiting
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
NCT07462650Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-01
Not yet open
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
NCT07014254Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach, Colorectal Cancer Metastatic, Neuroendocrine Tumor (NET)
Xijing Hospital
Not applicable
20
Xi'an
2025-06-20
Recruiting
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
NCT07050394Colorectal Cancer Metastatic, Colorectal Cancer Recurrent, Colorectal Cancer Stage IV
Shanghai Changzheng Hospital
Early Phase 1
20
Shanghai
2025-06-10
Recruiting
Sun Yat-sen University
Phase 1/2
64
Guangzhou
2025-06-01
By invitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
50
Hangzhou
2025-05-22
Recruiting
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
NCT06589830Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2
80
Beijing
2025-05-13
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
20
Hefei
2025-05
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
302
Hangzhou
2025-04-01
Recruiting
Fudan University
Phase 2
36
Shanghai
2025-02-26
Recruiting
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Not yet open
Fudan University
Phase 2
20
Shanghai
2024-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2024-11-12
Recruiting
Chinese PLA General Hospital
Phase 2
30
Beijing
2024-09-01
Recruiting
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
The First People's Hospital of Changzhou
Not applicable
30
Changzhou
2024-05-01
Recruiting
Fudan University
Phase 2
1,100
Shanghai
2023-12-28
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-10-25
Active, closed
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
NCT06792435Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
Astellas Pharma Global Development, Inc.
Phase 1/2
240
Jinan
2023-07-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Recruiting
Fudan University
Phase 2
25
Shanghai
2021-09-26
Active, closed
Sun Yat-sen University
Phase 1/2
36
Guangzhou
2021-06-16
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/colorectal-cancer-metastatic

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies listing the condition Colorectal Cancer Metastatic.

How many Colorectal Cancer Metastatic trials are recruiting in China?

19 of the 29 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorectal Cancer Metastatic), 29 studies
PhaseStudiesRecruitingShare
Phase 2161255.2%
Phase 1/25217.2%
Phase 33210.3%
Not applicable216.9%
Observational216.9%
Early Phase 1113.4%

Most active sponsors

Lead sponsors with the most studies (Colorectal Cancer Metastatic)
Lead sponsorStudiesRecruiting
Sun Yat-sen University64
Fudan University54
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Anhui Provincial Cancer Hospital10
Astellas Pharma Global Development, Inc.10
Beijing Biotech11
Chinese PLA General Hospital11
Dai, Guanghai11
Fujian Medical University Union Hospital10
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.